Corrigenda: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.

Autor: Patil, Sandeep T, Zhang, Lu, Martenyi, Ferenc, Lowe, Stephen L, Jackson, Kimberley A, Andreev, Boris V, Avedisova, Alla S, Bardenstein, Leonid M, Gurovich, Issak Y, Morozova, Margarita A, Mosolov, Sergey N, Neznanov, Nikolai G, Reznik, Alexander M, Smulevich, Anatoly B, Tochilov, Vladimir A, Johnson, Bryan G, Monn, James A, Schoepp, Darryle D
Předmět:
Zdroj: Nature Medicine; Oct2007, Vol. 13 Issue 10, p1264-1264, 1p
Abstrakt: A correction to the article "Corrigenda: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial" that was published in the September, 2007 issue is presented.
Databáze: Complementary Index